From IHUB’s falconer66a, Fletch falconer66a

New Post Public Reply Private Reply Replies (1) Message Board
fletch Drano #1036
801
From IHUB’s falconer66a,
Fletch

falconer66a Thursday, 06/04/20 02:41:21 PM
Re: None 0
Post # of 253611
Hope this is acceptable:

The superiority of Anavex against the other Alzheimer's treatments needs to be understood.

Ok, a new candidate drug is going to solve the Alzheimer’s problem, not by focusing on amyloid plaques or tau tangles, but by, somehow, improving the function of synapses (contact points between neurons).

Parties “are backing a drug — NDX-1017 — that bypasses the whole toxic plaque debate and focuses on another familiar strategy: the frayed synaptic network in the brain that erodes with the disease. Boost the network and you can stop, possibly reverse, the damage that corrodes cognition. For awhile.”

Well and good — if positive results appear with this new drug. But since the drug in no way addresses root causes of Alzheimer’s, which is the pathogenic non-clearance of wastes in neurons and nerves (the amyloid and tau proteins) those will continue to accumulate.

Understand, all sorts of potentially toxic wastes are continually produced by living cells, tissues, and organisms. Think not? Then don’t use a toilet for 24 hours; see how that works out.

This is where the mechanisms of action (MOA) of the Anavex sigma-1 receptor agonists separate themselves from all the other Alzheimer’s treatment approaches. Each of them (there are but a few), as with this new proposed drug, try to reduce only symptoms. For a period, this, to a degree, can happen. But sooner or later (usually sooner) the biochemical mechanisms of symptomatic suppression are overwhelmed. Fatal.

The real problem is the inability of neurons and nerves with Alzheimer’s to efficiently clear the biochemical wastes, before they can pathogenically accumulate. Here’s an analogy.

Your furnace, in winter, produces toxic waste gases, including carbon dioxide and carbon monoxide. Your furnace, normally and properly, voids these wastes out of the chimney. Well and good.

But how do you “treat” your furnace if a carbon monoxide sensor in your hallway goes off? “Whoa, something’s wrong.” Carbon monoxide is both odorless and fatal (in high concentrations). So, you turn off your furnace, and call the HVAC contractor to fix the problem.

But you could have dealt with it like the current Alzheimer’s drugs do. Treat the symptoms, not the causes of them. Very simple. Just open the windows to allow enough fresh air into the room so as to sufficiently dilute the carbon monoxide. That would work, would it not? Well, until it got really cold.

The solution to both problems, Alzheimer’s and a furnace leaking carbon monoxide into the heating airstreams of a house, is to fix the root cause. In the case of the furnace, find the corroded gap in the fire chamber, and replace it with a new one (or, an entire new furnace). Problem solved.

In the case of Alzheimer’s, biochemically arrange for the restoration of the normalized clearance of wastes. With that, Alzheimer’s is impossible. No pathological accumulation of wastes; neither beta-amyloids or tau tangles. Nerves function normally.

How, then, is this arranged? But ingesting (orally) small amounts of blarcamesine, AKA Anavex 2-73. By its activation of the sigma-1 receptor protein (among other things) this proprietary molecule allows the cell to resume normalized function. “Homeostasis” (feedback-controlled cell processes) is restored. Wastes cannot accumulate. Before they do, their increasing concentration is detected by the cell which, then, turns on increased waste-clearance processes (the cell uses the toilet frequently, as it were).

Essential to all homeostatic processes (and many others) in the cell (especially with age) is the proper folding of proteins into fully functioning enzymes. Blarcamesine causes this. With that, wastes can be enzymatically rendered and compartmentalized into waste-clearing structures before they are pathogenic. Problem solved.

Anavex solves the Alzheimer’s problem at the top, at the start of the cascade of processes that result in the disease. All of the other treatment approaches deal, ever so inadequately or briefly, with only “downstream” factors. The problems continue.

Anavex is way better.

https://investorshub.advfn.com/boards/read_ms...=156058332

Anavex Life Sciences Corp. (AVXL) Stock Research Links

AVXL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytokinetics Faces Class Action: What You Need to Know

Updated Category News Views 175

Understanding the Class Action Lawsuit Against Cytokinetics Cytokinetics, Incorporated is currently facing a significant class action lawsuit initiated by shareholders. This legal challenge brings to light serious allegations against the Company regarding their disclosures and expectations for FDA approval of a key drug. Details of the Allegations The lawsuit asserts that...

Continue Reading
Discover the Embodied Luxury of the Champagne Specialist Course

Updated Category News Views 207

Verona Hosts the Esteemed Champagne Specialist Course The Italian Wine Academy is excited to announce a remarkable opportunity for wine enthusiasts and professionals. In Verona, for the very first time, the Academy will conduct the prestigious Comité Champagne 'Champagne Specialist' course. This unique program will be available in both English and Italian, providing an...

Continue Reading
MiniLuxe Achieves Strong Q1 2025 Growth with Strategic Focus

Updated Category News Views 378

MiniLuxe Reports Strong Financial Performance for Q1 2025 Reported figures all in U.S. Dollars MiniLuxe Holding Corp. (TSXV: MNLX) has announced exciting financial results for its first quarter of the year. This period showcased a significant 9% growth in revenue, reaching an impressive $6.1 million. Coupled with a gross profit of $2.5 million, reflective of a 12%...

Continue Reading
Transforming Shopify: AI Product Discovery for Enterprises

Updated Category News Views 141

Fredhopper's New App for Shopify Fredhopper Introduces Cutting-Edge Product Discovery Solutions The ecommerce landscape is evolving rapidly, and innovation is at the forefront. Fredhopper has launched its Product Discovery App for Shopify, bringing advanced AI-powered product search and personalized recommendations directly into the hands of enterprise merchants. This...

Continue Reading
Quantum Computing Inc. Faces Class Action Lawsuit for Shareholders

Updated Category News Views 162

Understanding the Recent Class Action Against Quantum Computing Inc. In a significant turn of events, Quantum Computing Inc. has come under legal pressure as a class action lawsuit has been filed on behalf of its shareholders. The lawsuit comes in response to allegations of misleading information that may have adversely affected investors' financial interests. Class...

Continue Reading